comparemela.com

Latest Breaking News On - Company or scisparc - Page 4 : comparemela.com

SciSparc Ltd Announces $20 Million Standby Equity Purchase

TEL AVIV, Israel, Jan. 24, 2024 (GLOBE NEWSWIRE) SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical.

United statesScisparc ltdExchange commissionYa ii pn ltdCompany or scisparcYorkville advisors globalSecurities actTourette syndromeLooking statementsAnnual reportNasdaq sprcScisparc ltd

SciSparc Ltd Announces $20 Million Standby Equity Purchase Agreement

TEL AVIV, Israel, Jan. 24, 2024 SciSparc Ltd. , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central.

United statesGlobenewswire incCompany or scisparcYa ii pn ltdExchange commissionScisparc ltdAdvisors globalSecurities actTourette syndromeLooking statementsAnnual report

SciSparc Advances the Acquisition Process of a Leading

TEL AVIV, Israel, Jan. 19, 2024 (GLOBE NEWSWIRE) SciSparc Ltd. (Nasdaq: SPRC) (

Scisparc ltdExchange commissionCompany the acquisitionCompany or scisparcTarget companyBridge loanOwed amountTourette syndromeLooking statementsPrivate securities litigation reform actAnnual reportNasdaq sprcScisparc ltd

SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1 4 million

TEL AVIV, Israel, Jan. 19, 2024 SciSparc Ltd. , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central.

Company the acquisitionCompany or scisparcScisparc ltdExchange commissionTarget companyBridge loanOwed amountTourette syndromeLooking statementsPrivate securities litigation reform actAnnual report

SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments

The collaboration included six different provisional patent applications filed by Clearmind with the United States Patent and Trademark Office in February 2023 to protect the novel combinations of.

United statesTrademark officeExchange commissionScisparc ltdClearmind medicine incCompany or scisparcUnited states patentClearmind medicineTourette syndromeLooking statementsPrivate securities litigation reform actAnnual report

vimarsana © 2020. All Rights Reserved.